RNA Editing and Epitranscriptomics: Emerging Tools for Precision Medicine

By Dr. Priyom Bose, Ph.D.Reviewed by Lauren Hardaker

The Rise and Advances in Epitranscriptomics
Oligonucleotide Approaches to Epitranscriptomic Modulation
Emerging Therapeutic and Diagnostic Opportunities
Challenges and Future Directions in Epitranscriptomics
References and Further Reading

Advances in detection technologies and RNA-targeting oligonucleotides have revealed both the therapeutic promise and technical limitations of manipulating RNA modifications, positioning epitranscriptomics as a rapidly evolving but still maturing field in precision medicine. 

Image credit: Love Employee/Shutterstock.com

RNA modifications, collectively referred to as epitranscriptomic modifications, represent a rapidly expanding area of research in molecular biology. Oligonucleotide-based technologies now allow sequence-specific targeting of RNA and recruitment of endogenous modification or editing machinery, enabling novel therapeutic approaches. By altering epitranscriptomic marks with oligonucleotides, researchers can correct disease-associated RNA changes and pave the way for tailored, effective treatments.^1,2

The Rise and Advances in Epitranscriptomics

Beyond serving as templates for protein synthesis, RNAs play diverse roles in cellular regulation. Chemical modifications of RNA play critical roles in regulating RNA stability, translation efficiency, alternative splicing, RNA localization, and nuclear-to-cytoplasmic RNA transport. Disruption or dysregulation of these modifications has been linked to a broad spectrum of biological processes and diseases, highlighting their importance in regulating gene expression and cellular homeostasis.³

Early studies primarily focused on abundant RNA species, such as ribosomal RNA (rRNA) and transfer RNA (tRNA), and established that these molecules undergo extensive post-transcriptional modifications essential for their structural integrity and biological function. Over the years, technological advances, including next-generation RNA sequencing and high-throughput analyses, have enabled the identification of RNA modifications in low-abundance RNA species. However, detection sensitivity and accuracy remain dependent on method-specific biases, particularly reverse transcription–based artifacts.¹¹

A major epitranscriptomics breakthrough occurred in 2011 when researchers demonstrated that the internal RNA modification N6-methyladenosine (m6A) is dynamically regulated via reversible addition and removal, with the fat mass and obesity-associated protein (FTO) acting as a demethylase. This discovery provided compelling evidence that RNA modifications are not only widespread but also reversible and functionally impactful, catalyzing a surge of research and technological innovation in epitranscriptomics.⁴

To date, more than 170 distinct chemical modifications have been identified in both coding and non-coding RNAs, highlighting the remarkable chemical diversity found in the transcriptome. Some of the most prominent modifications include N6-methyladenosine (m⁶A), 5-methylcytosine (m⁵C), pseudouridine (Ψ), N1-methyladenosine (m¹A), and N4-acetylcytidine (ac⁴C). These modifications are distributed among a variety of RNA classes, such as messenger RNA (mRNA), tRNA, rRNA, and small nuclear RNA (snRNA). They are installed by specific writer enzymes and removed by erasers, with dedicated reader proteins that recognize and interpret these marks, collectively forming a dynamic regulatory system that controls RNA fate.^1,5

Download the free PDF for deeper insights into RNA modifications and therapeutic strategies.

Oligonucleotide Approaches to Epitranscriptomic Modulation

Oligonucleotides are short, synthetic DNA or RNA strands that bind to specific RNA or DNA sequences through complementary base pairing. This sequence specificity enables them to direct or block cellular machinery at targeted RNA sites. As a result, oligonucleotides are central to diverse epitranscriptomic modification strategies that allow scientists to regulate RNA function, stability, and modification states with high precision. These molecules can act via multiple mechanisms, including RNase H-mediated degradation, steric blocking, or recruitment of RNA-modifying enzymes.^2,7 The key strategies are discussed below:

Targeted RNA Editing

Targeted RNA editing uses guide oligonucleotides to recruit endogenous enzymes, such as adenosine deaminase acting on RNA (ADAR), to precisely convert adenosine (A) to inosine (I) at specific sites in RNA molecules. This approach enables reversible correction of pathogenic mutations at the RNA level, reducing off-target risks compared to permanent genome editing. However, current systems still face challenges, including off-target editing, bystander effects, and delivery limitations. Scientists are actively working on improving the specificity, efficiency, and delivery of these guides for clinical use.⁶

Modulating RNA–Protein Interactions

Oligonucleotides, including antisense oligonucleotides (ASOs) and splice-switching oligonucleotides (SSOs), directly regulate gene expression by sterically blocking or allosterically modulating the binding of trans-acting factors, such as RNA-binding proteins (RBPs) or spliceosome components, to their target RNA motifs. Through sequence-specific hybridization, these oligonucleotides can competitively inhibit or displace regulatory proteins, thereby altering RNA stability, alternative splicing patterns, subcellular localization, and translational efficiency. These mechanisms are well-established clinically, with multiple approved ASO drugs acting via RNase H-dependent degradation or splice modulation. This molecular precision facilitates targeted manipulation of gene expression profiles and expands the therapeutic landscape by enabling intervention at the level of RNA modification and processing.⁷

Structural and Site-Specific Targeting

Oligonucleotide-based approaches can induce local conformational changes in RNA or sterically occlude specific modification sites, providing precise spatial and temporal control over epitranscriptomic marks such as methylation or editing. Such strategies may influence the accessibility of modification enzymes or reverse transcription signatures used for detection. By manipulating RNA secondary structure or accessibility, these strategies enable targeted modulation of RNA processing, stability, and function, supporting both mechanistic studies and therapeutic interventions.^2,11

Emerging Therapeutic and Diagnostic Opportunities

Recent technical advances, such as nanopore direct RNA sequencing (DRS), single-nucleotide-resolution sequencing, and single-cell analysis, now enable scientists to identify abnormal patterns of RNA modifications or disruptions in enzymes that mediate chemical modifications associated with a variety of diseases, including cancer, metabolic disorders, infectious diseases, and neurological disorders. These approaches complement traditional antibody-based and mass spectrometry techniques, each with distinct strengths and limitations in sensitivity and resolution. These breakthroughs provide the foundation for both therapeutic and diagnostic innovations in epitranscriptomics.⁸

Building on these advances, the therapeutic market for epitranscriptomics is rapidly expanding, enabling the development of highly targeted interventions that alter RNA modifications implicated in disease. For example, inhibitors of the m⁶A 'writer' enzyme METTL3 have shown potential in preclinical models by disrupting oncogenic RNA methylation patterns, thereby impeding tumor growth. This technical approach highlights the promise of epitranscriptomic drug discovery in creating precision therapies for complex diseases such as cancer. Indeed, METTL3-mediated m6A regulation has been directly linked to proliferation, metabolism, and drug resistance pathways in malignancies.⁹

Beyond therapeutics, these technological breakthroughs are also fueling the diagnostic potential of epitranscriptomics, particularly in complex diseases such as type 2 diabetes mellitus (T2DM). Traditional biomarkers, including fasting glucose and hemoglobin A1c (HbA1c), play important roles in diagnosis and disease monitoring but often lack the sensitivity to predict disease progression or capture underlying molecular changes. Recent studies have identified altered levels of m6A and its regulatory proteins, including FTO and METTL3, in the blood of individuals with T2DM, suggesting their potential utility for early detection and disease stratification.¹⁰

Video credit: VJOncology/Youtube.com

Challenges and Future Directions in Epitranscriptomics

Although notable advances have been made, epitranscriptomics continues to face several technical and conceptual challenges. Existing RNA modification detection methodologies often exhibit limitations in sensitivity, specificity, and throughput, hindering the generation of comprehensive, high-resolution modification maps across diverse biological systems. In particular, sequencing-based approaches relying on reverse transcription can introduce biases and noise that complicate interpretation and quantification.¹¹

Numerous RNA modifications remain largely uncharacterized, with limited understanding of their distinct biochemical functions and influence on cellular processes and disease states. Additionally, the development of selective and efficacious modulators for a broader spectrum of RNA modification enzymes remains in its infancy, restricting translational applications beyond m⁶A and oncology-focused research.

Looking ahead, the trajectory of epitranscriptomics is both promising and complex. Addressing current limitations will require sustained innovation in detection platforms, including the adoption of long-read sequencing technologies and the implementation of advanced computational algorithms.

Broadening the scope of research to systematically investigate a wider array of RNA modifications and biological contexts is essential for unraveling regulatory intricacies. Achieving meaningful progress will rely on robust interdisciplinary collaboration among chemical biologists, genomics experts, computational scientists, and clinicians to effectively translate foundational discoveries into clinical applications. By systematically overcoming these persistent barriers, the field stands poised to enable novel strategies in diagnostics, therapeutics, and precision medicine, thereby enhancing the likelihood of interrogating and modulating gene regulation at the RNA level.

References and Further Reading

1. Artika IM, et al. RNA modifications and their role in gene expression. Front Mol Biosci. 2025;12:1537861. DOI:10.3389/fmolb.2025.1537861, https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1537861/full
2. Adachi H, et al. From Antisense RNA to RNA Modification: Therapeutic Potential of RNA-Based Technologies. Biomedicines. 2021;9(5):550. DOI:10.3390/biomedicines9050550, https://www.mdpi.com/2227-9059/9/5/550
3. Qiu L, et al. RNA modification: mechanisms and therapeutic targets. Mol Biomed. 2023;4(1):25. DOI:10.1186/s43556-023-00139-x, https://link.springer.com/article/10.1186/s43556-023-00139-x.
4. Yan S, et al. Epitranscriptomic Role of m6A in Obesity-Associated Disorders and Cancer Metabolic Reprogramming. Genes (Basel). 2025;16(5):498. DOI:10.3390/genes16050498, https://www.mdpi.com/2073-4425/16/5/498.
5. Tian L, et al. Advances in Quantitative Techniques for Mapping RNA Modifications. Life (Basel). 2025;15(12):1888. DOI:10.3390/life15121888, https://www.mdpi.com/2075-1729/15/12/1888.
6. Borkiewicz L. Evolution of Engineered ADAR-Based RNA Editing Systems. Int J Mol Sci. 2026;27(4):1858. DOI:10.3390/ijms27041858, https://www.mdpi.com/1422-0067/27/4/1858
7. Chen S, et al. Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases. BioDrugs. 2024;38(2):177-203. DOI:10.1007/s40259-024-00644-7, https://link.springer.com/article/10.1007/s40259-024-00644-7.
8. Cerneckis J, et al. The rise of epitranscriptomics: recent developments and future directions. Trends Pharmacol Sci. 2024;45(1):24-38. DOI:10.1016/j.tips.2023.11.002, https://linkinghub.elsevier.com/retrieve/pii/S0165614723002547.
9. Prajapati S, et al. The role of m6A RNA methyltransferase METTL3 in drug resistance mechanisms in acute myeloid leukemia. Blood Res. 2026;61(1):7. DOI:10.1007/s44313-026-00123-8, https://link.springer.com/article/10.1007/s44313-026-00123-8.
10. Hlavackova M, et al. Epitranscriptomic signatures in blood: emerging biomarkers for diagnosis of diabetes and its complications. Front Cell Dev Biol. 2025;13:1656769. DOI:10.3389/fcell.2025.1656769, https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1656769/full.
11. Motorin Y, Helm M. General Principles and Limitations for Detection of RNA Modifications by Sequencing. Acc Chem Res. 2024;57(3):275-288. DOI:10.1021/acs.accounts.3c00529, https://pubs.acs.org/doi/10.1021/acs.accounts.3c00529.

Last Updated: Apr 23, 2026